Amarin (AMRN) gives an update on sales of Vascepa. Rundown for the first five months of marketing and selling (from the PR, which comes with a host of caveats): "3,224 (Feb); 7,260 (Mar); 12,314 (Apr); and 16,076 (May); 18,367 (June)." The June data excludes the last two days of the month and is based on weekly compilations which the company says "generally tend to understate the number of prescriptions in the monthly compilations." "Rx growth M/M since launch: 125%, 70%, 31%, 14%," notes theStreet's Adam Feuerstein.
Market Data 
Markets 
AI
